Galecto, Inc.

Contributing Author

Recent Articles by Galecto, Inc.

Mar-09	Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders GlobeNewswire
Mar-04	Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-02	Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference GlobeNewswire
Feb-12	Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million GlobeNewswire
Feb-10	Galecto Announces Pricing of $275 Million Underwritten Public Offering GlobeNewswire
Feb-10	Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock GlobeNewswire
Jan-12	Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones GlobeNewswire
Jan-06	Galecto Announces Key Additions to Leadership Team GlobeNewswire
Dec-16	Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-10	Galecto Announces Acquisition of Damora Therapeutics GlobeNewswire
Nov-06	Galecto Reports Third Quarter 2025 Operating and Financial Results GlobeNewswire
Nov-03	Galecto to Highlight GB3226 Program at ASH 2025 GlobeNewswire
Aug-05	Galecto Reports Second Quarter 2025 Operating and Financial Results GlobeNewswire
May-08	Galecto Reports First Quarter 2025 Operating and Financial Results GlobeNewswire